Gjini, E., Trillo-Tinoco, J., Browne, A., Powles, R., Wang, T., Tauras, C., Lako, A., Ferrer-Luna, R., Bleicher, Z., Consedine, T., Zhou, C., Kelemen, E., Lewin, A., King, C., Bhattacharya, S., Bell-Temin, H., Dongre, A., Nelson, D., Hatzis, C., Macisaac, K., Towfic, F., Chen, B., & Bowden, M. (n.d.). 733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy. Journal for immunotherapy of cancer, 8, A777. http://access.bl.uk/ark:/81055/vdc_100144727094.0x000001